Treatment of hyperlipidemia

Journal of Family Practice

Volumn 51, Issue 4, 2002, Pages 370-376

  Henley, Eric ^a   Chang, Linda ^a   Hollander, Sue ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Dietary supplements; Herbal; Hyperlipidemia; Lifestyle; Medication; Risk assessment; Therapy

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; COLESTYRAMINE; GEMFIBROZIL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; STATINE;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; FLUSHING; GASTROINTESTINAL DISEASE; GENERAL PRACTITIONER; HEPATITIS; HUMAN; HYPERLIPIDEMIA; LIFESTYLE; MASS SCREENING; META ANALYSIS; MYOPATHY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT;

ADULT; AGED; ALGORITHMS; ANTILIPEMIC AGENTS; CORONARY DISEASE; DIETARY SUPPLEMENTS; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIFE STYLE; MALE; MIDDLE AGED; PHYTOTHERAPY; PRACTICE GUIDELINES; RISK ASSESSMENT;

EID: 0036220653     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. National Ambulatory Medical Care Survey 1995-1996 summary
2. Dietary treatment of hyperlipidemia: Do dietitians do it better? A randomized, controlled trial
3. Avoiding revascularization with lifestyle changes: The multicenter lifestyle demonstration project
4. Intensive lifestyle changes for reversal of coronary heart disease
5. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term. Intense risk factor modification
6. Efficacy of dietary plant stanols
7. Incremental reduction of serum total cholesterol and LDL with the addition of plant stanol ester-containing spread to statin therapy
8. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesteremic population
9. Evaluation of the antihyperlipidemic properties of dietary supplements
10. Nonpharmacologic treatment of hypertriglyceridemia: Focus on fish oils
11. Garlic for treating hyperlipidemia
12. Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia
13. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease
14. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
15. Prevention of coronary heart disease with pravastatin in men with hyperlipidemia
16. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
17. Use of lipid lowering drugs for primary prevention of coronary heart disease: Meta-analysis of randomized trials
18. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) Study
19. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of HDL-cholesterol
20. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S)
21. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease
22. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
23. Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin
24. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials
25. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hyperlipidemia
26. Medications that require hepatic monitoring
27. What lab monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents?
28. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes
29. Comparative dose efficacy study of atorvastatin vs. Simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hyperlipidemia (the CURVES study)